Massive Bio has signed a strategic partnership with Just Worldwide to connect more cancer patients to clinical studies.
The collaboration will leverage established patient communities, advocacy groups, and AI-driven trial matching.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Under this partnership, Just Worldwide will utilise its engagement infrastructure to increase awareness of Massive Bio’s clinical trials.
The company will onboard interested patients through its established channels, facilitate the collection of medical records, and support the full process from patient interest to trial eligibility assessment.
Just Worldwide’s experience with multicultural teams, including senior recruiters, project managers, and patient engagement specialists, allows it to reach patient populations that are typically harder to engage.
By combining Just Worldwide’s fieldwork capabilities with Massive Bio’s SYNERGY-AI platform, the partnership creates a pipeline that initiates at the community level and concludes with patients being matched to appropriate clinical trials.
Massive Bio has so far facilitated over 17,000 oncologist-confirmed clinical trial matches across more than 17 countries.
Massive Bio co-founder and chief medical AI officer Arturo Loaiza-Bonilla said: “As oncologists, we know that the right clinical trial can be a turning point for a patient – but only if they know it exists.
“Just Worldwide’s ability to engage patients and advocacy communities at scale, combined with Massive Bio’s AI matching engine, creates a system where the right information finds the right patient at exactly the right moment in their journey.”
Massive Bio’s SYNERGY-AI platform will assess eligibility and match patients to relevant trials.
Massive Bio chief financial officer Toygun Rauf Onaran said: “This partnership addresses that gap by channelling patients through trusted community networks directly into our matching infrastructure. The model is scalable, compliant, and built to deliver measurable impact on enrolment rates.”
Last month, Massive Bio entered a partnership with OpenAI to expand global access to clinical studies through AI-driven parameterisation of protocols and real-time patient pre-screening.
